Institute of Biopharmaceutical, Zhejiang Pharmaceutical College, Zhejiang Province, Ningbo 315100, PR China.
Institute of Biopharmaceutical, Zhejiang Pharmaceutical College, Zhejiang Province, Ningbo 315100, PR China.
J Pharmacol Sci. 2020 May;143(1):45-51. doi: 10.1016/j.jphs.2020.01.009. Epub 2020 Feb 28.
The leaves of Lindera aggregate (Sims) Kosterm. are traditionally used as healthy tea for the prevention and treatment of hyperlipidemia in Chinese. The aim of this study was to evaluate the antihyperlipidemic effects and potential mechanisms of the aqueous extracts from L. aggregate leaves (AqLA-L) on normal and hypercholesterolemic (HCL) mice. HCL mice were induced by high fat diet (HFD) and orally administrated with or without AqLA-L for ten days. The results showed that AqLA-L (0.3, 0.6, 1.2 g/kg) significantly reduced serum TG, ALT, but elevated fecal TG in normal mice. AqLA-L (0.3, 0.6, 1.2 g/kg) also remarkably lowered serum TC, TG, LDL, N-HDL, ALT, GLU, APOB, hepatic GLU and increased serum HDL, APOA-I, fecal TG levels in HCL mice. These results revealed that AqLA-L treatment regulated the disorders of the serum lipid and liver function, reduced hepatic GLU contents both in normal and HCL mice. The potential mechanisms for cholesterol-lowering effects of AqLA-L might be up-regulation of cholesterol 7-alpha-hydroxylase (CYP7A1) and ATP-binding cassette transporter A1 (ABCA1), as well as down-regulation of 3-hydroxy-3-methylglutaryl CoA reductase (HMGCR). The data indicated that AqLA-L has potential therapeutic value in treatment of hyperlipidemia with great application security.
由积状安息香（Sims）Kosterm. 的叶子在中医中被传统地用作预防和治疗高血脂的健康茶。本研究旨在评估积状安息香叶水提物（AqLA-L）对正常和高胆固醇血症（HCL）小鼠的降血脂作用及潜在机制。通过高脂饮食（HFD）诱导 HCL 小鼠，并连续 10 天给予 AqLA-L 或不给予 AqLA-L 进行口服处理。结果表明，AqLA-L（0.3、0.6、1.2 g/kg）可显著降低正常小鼠血清 TG、ALT，但可升高粪便 TG。AqLA-L（0.3、0.6、1.2 g/kg）还可显著降低 HCL 小鼠血清 TC、TG、LDL、N-HDL、ALT、GLU、APOB、肝 GLU，增加血清 HDL、APOA-I、粪便 TG 水平。这些结果表明，AqLA-L 治疗可调节血清脂质和肝功能紊乱，降低正常和 HCL 小鼠肝 GLU 含量。AqLA-L 降低胆固醇作用的潜在机制可能是上调胆固醇 7-α-羟化酶（CYP7A1）和三磷酸腺苷结合盒转运蛋白 A1（ABCA1），以及下调 3-羟-3-甲基戊二酰辅酶 A 还原酶（HMGCR）。数据表明，AqLA-L 在治疗高血脂方面具有潜在的治疗价值，且应用安全性高。
